Padagis Israel Pharmaceuticals Ltd: Company Profile
Background
Overview
Padagis Israel Pharmaceuticals Ltd is a leading pharmaceutical company dedicated to improving the well-being of patients and consumers by developing, manufacturing, and distributing high-quality, affordable specialized healthcare products. The company offers a diverse portfolio that includes prescription medications, biosimilars, non-prescription drugs, generic drugs, glucose meters, medical equipment, and consumer products. Its clientele comprises hospitals, health funds, pharmacies, and pharmacy chains across institutional and private markets.
Mission and Vision
Padagis Israel is committed to enhancing patient care by providing accessible and effective pharmaceutical solutions. The company's vision is to be a trusted partner in healthcare, delivering innovative products that meet the evolving needs of the global market.
Industry Significance
Established in 1961 as "Agis," the company has been a significant player in the Israeli pharmaceutical industry. In 2005, Agis was acquired by Perrigo Company PLC, a prominent U.S.-based over-the-counter pharmaceutical company. In 2021, the prescription pharmaceuticals business was sold to the Altaris Fund, a venture capital fund specializing in the medical field. Padagis Israel currently employs approximately 850 individuals and is one of the largest employers in the Negev area.
Key Strategic Focus
Core Objectives
Padagis Israel focuses on delivering a comprehensive range of pharmaceutical products that cater to both prescription and over-the-counter markets, emphasizing quality, affordability, and patient-centric solutions.
Areas of Specialization
- Prescription Medications: Developing and manufacturing a wide array of prescription drugs across various therapeutic areas.
- Biosimilars: Entering the biosimilars market with products such as insulin and monoclonal antibodies.
- Non-Prescription Drugs: Offering over-the-counter medications, including pain relievers, cold and flu remedies, and gastrointestinal products.
- Consumer Health Products: Providing vitamins, supplements, and wellness products.
Key Technologies Utilized
Padagis Israel employs advanced manufacturing technologies compliant with Good Manufacturing Practice (GMP) standards to ensure product quality and safety. The company also invests in research and development to innovate and improve its product offerings.
Primary Markets Targeted
The company primarily serves the Israeli market, with a growing presence in international markets through strategic partnerships and distribution agreements.
Financials and Funding
Funding History
Specific details regarding Padagis Israel's funding history are not publicly disclosed. However, the company's strategic decisions, such as the sale of its prescription pharmaceuticals business to the Altaris Fund in 2021, indicate active management of its financial resources to align with its strategic objectives.
Recent Funding Rounds
Information about recent funding rounds is not publicly available.
Notable Investors
The Altaris Fund, a venture capital fund specializing in the medical field, acquired Padagis Israel's prescription pharmaceuticals business in 2021.
Utilization of Capital
The capital from the sale to the Altaris Fund has likely been allocated to strengthen Padagis Israel's focus on its core competencies, including the development and distribution of non-prescription drugs, biosimilars, and consumer health products.
Pipeline Development
Key Pipeline Candidates
Padagis Israel is actively involved in the development of biosimilars, with a focus on products such as insulin and monoclonal antibodies. The company is also expanding its portfolio of non-prescription drugs and consumer health products to meet market demands.
Stages of Development
The company is in various stages of development for its pipeline products, including preclinical research, clinical trials, and market preparation.
Target Conditions
For biosimilars, the target conditions include diabetes (insulin) and various diseases treated with monoclonal antibodies. Non-prescription drugs and consumer health products address a wide range of common health concerns.
Anticipated Milestones
Specific timelines for product development milestones are not publicly disclosed.
Technological Platform and Innovation
Proprietary Technologies
Padagis Israel utilizes proprietary manufacturing processes that adhere to GMP standards, ensuring the production of high-quality pharmaceutical products.
Significant Scientific Methods
The company employs advanced scientific methodologies in its research and development processes, including formulation development, stability testing, and bioequivalence studies.
AI-Driven Capabilities
While specific details about AI-driven capabilities are not publicly available, Padagis Israel's commitment to innovation suggests potential integration of advanced technologies in its operations.
Leadership Team
Key Executives
- Shlomi Leibovich: Senior Vice President and CEO of Padagis Israel.
Professional Backgrounds and Contributions
Shlomi Leibovich has been instrumental in leading Padagis Israel through strategic transitions, including the sale of the prescription pharmaceuticals business and the expansion into biosimilars and non-prescription drugs.
Competitor Profile
Market Insights and Dynamics
The pharmaceutical market in Israel is characterized by a mix of multinational corporations and local companies. Padagis Israel competes with both, focusing on niche markets such as biosimilars and non-prescription drugs.
Competitor Analysis
Key competitors include multinational companies like Teva Pharmaceutical Industries and local firms such as Dexcel Pharma. Teva offers a broad portfolio of generic and specialty medicines, while Dexcel Pharma focuses on generic drugs and over-the-counter products.
Strategic Collaborations and Partnerships
Significant Collaborations
- Moberg Pharma: In August 2022, Padagis Israel signed a distribution agreement with Moberg Pharma for the marketing and sale of MOB-015 in Israel and the Palestinian territories.
- Medisca: In January 2022, Medisca became the exclusive global distributor outside the USA and Israel for Padagis's ORA product line.
Operational Insights
Strategic Considerations
Padagis Israel's strategic focus on biosimilars and non-prescription drugs positions it to leverage growing market demand for affordable healthcare solutions. The company's manufacturing facilities in Yeruham and Shoham provide a strong operational foundation to support its product development and distribution efforts.
Strategic Opportunities and Future Directions
Expansion Plans
Padagis Israel aims to expand its presence in the biosimilars market and enhance its portfolio of non-prescription drugs and consumer health products. The company is also exploring opportunities for geographic diversification to tap into emerging markets.
Future Objectives
The company's future objectives include strengthening its position in the pharmaceutical industry by focusing on innovation, quality, and patient-centric solutions.
Contact Information
Website
Padagis Israel Official Website
Social Media
- LinkedIn: Padagis Israel LinkedIn Profile
Padagis Israel continues to evolve, focusing on strategic growth areas and maintaining its commitment to delivering high-quality pharmaceutical products to meet the needs of patients and consumers.
